Current Report · Items 8.01, 9.01 · 8-K
OS Therapies Incorporated
OSTXNYSE_AMERICANEQUITYCurrent
Other Events
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description ─────────────────────────────────────────────────────────────────────────────────────────────────────────── 5.1 Opinion of Olshan Frome Wolosky LLP. 23.1 Consent of Olshan Frome Wolosky LLP (included in its opinion filed as Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Company context
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in gene-edited, Listeria-based cancer immunotherapies. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 is designed to target two mutated extracellular epitopes and one mutated intracellular epitope of the HER2 oncogene, requiring only one of these three epitopes to be present in a tumor (or micro-metastasis) to trigger the desired immune response. OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and has received ODD, FTD, and Advanced Therapy Medicinal Products (ATMP) from the European Medicines Agency.
Current securities
Recent company filings
- 3 filingOct 5, 2026
- Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsOct 5, 2026
- S-8 filingSep 21, 2026
- 424B7 filingSep 10, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersSep 9, 2026